UQCRB and glioma: Finally, we identified drugs as mitochondria-related therapeutic targets for gliomas and used molecular docking to demonstrate that UQCRB binds covalently to Amonafide via lysine at position 78 and threonine at position 82, and that cellular assays suggest that Amonafide inhibits migration and invasion of gliomas.